Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Tenax Therapeutics shares plunged 87.2% after the company's heart drug failed to meet the primary endpoint in a late-stage study.

Tenax Therapeutics shares plunged 87.2% after the company's heart drug failed to meet the primary endpoint in a late-stage study.

智通财经智通财经2026/08/10 13:41
Show original
Tenax Therapeutics shares plunged 87.2% after the company's heart medication failed to meet its primary endpoint in a late-stage study.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!